eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
5/2023
vol. 40
 
Share:
Share:
abstract:
Review paper

The efficacy of metformin for the treatment of psoriasis: a meta-analysis study

Zhuo Huang
1, 2, 3
,
Jianhua Li
1, 2
,
Hongbo Chen
1, 2, 3
,
Dan Yu
1, 2, 3
,
Shuwen Sun
1, 2

  1. Department of Paediatrics, West China Second University Hospital, Sichuan University, Chengdu, China
  2. Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China
  3. Department of Medical Genetics, West China Second University Hospital, Sichuan University, Chengdu, China
Adv Dermatol Allergol 2023; XL (5): 606-610
Online publish date: 2023/08/22
View full text Get citation
 
Introduction and aim:
Metformin has potential in treating patients with psoriasis, and this meta-analysis aims to explore the impact of metformin supplementation on treatment efficacy for psoriasis.

Material and methods:
The PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched, and we included randomized controlled trials (RCTs) assessing the effect of metformin on treatment efficacy for patients with psoriasis.

Results:
Three RCTs were included in the meta-analysis. Overall, compared with control intervention for psoriasis, metformin intervention resulted in significantly increased psoriasis area severity index (PASI) 75% reduction (odds ratio (OR) = 22.02; 95% confidence interval (CI): 2.12 to 228.49; p = 0.01), and erythema, scaling and induration (ESI) 75% reduction (OR = 9.12; 95% CI: 2.13 to 39.02; p = 0.003), and was associated with substantially decreased fasting plasma glucose (FPG, standard mean difference (SMD) = –0.59; 95% CI: –0.92 to –0.26; p = 0.0005), triglycerides (SMD = –0.92; 95% CI: –1.38 to –0.47; p < 0.0001), total cholesterol (SMD = –0.77; 95% CI: –1.22 to –0.32; p = 0.00008), and low-density lipoprotein (LDL, SMD = –0.67; 95% CI: –1.12 to –0.23; p = 0.003).

Conclusions:
Metformin supplementation effectively improves treatment efficacy and metabolic syndrome in psoriasis patients.

keywords:

psoriasis, metformin supplementation, treatment efficacy, meta-analysis

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.